Peer Review History

Original SubmissionNovember 28, 2024
Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

Decision Letter - Amir Hossein Behnoush, Editor

Dear Dr. pei,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 22 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Amir Hossein Behnoush

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

[This study was supported by two major projects of Hunan Province, China: 2021SK2004; 2021SK1040;c].

Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition ).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories .

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: Dear Authors, I had the privilege to review the manuscript PONE-D-24-54649 entitled "Association of predicted lean body mass and fat mass with prognosis in patients with heart failure preserved ejection fraction" for possibile publication in PLOS one.

In this trial you evaluated the role of lean BMI and FMI in a cohort of HF patients enrolled in the TOPCAT trial showing that a lower Lean BMI and a higher FMI were associated with an increased risk of primary endpoint events and all-cause mortality. The limits of a BMI only-centred evaluation in HF are already well known being the base of the "obesity paradox" concept, as you also explain in your manuscript.

Trying to estimate the body composition in HF patients is, therefore, important from a prognostic point of view.

My evaluation includes a positive feedback.

I suggest to expand the discussion section including more previous studies and trying to suggest more clinical implication. Moreover, could you analyze the impact of spironolactone in different lean BMI/FMI subgroups?

Reviewer #2: This manuscript is well-written, to-the-point, and statistically accurate. I have one point to recommend:

Several studies have shown that it is the waist circumference (and not BMI) that is a significant risk factor for many cardiovascular disorders and cardiovascular events. I believe at least some of these studies must be discussed in your manuscript since visceral fat, lean body mass, and fat mass are greatly emphasizing the waist circumference over BMI. Here are some articles that I recommend to add to your manuscript: PMID: 32020062 (discusses importance of waist circumference) ,PMID: 37227560 ( shows significant association between major cardiovascular events including heart failure and waist circumference, I highly recommend both)

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes:  Massimo Mapelli

Reviewer #2: Yes:  Alireza Ramandi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org

Revision 1

1. I suggest to expand the discussion section including more previous studies and trying to suggest more clinical implication. Moreover, could you analyze the impact of spironolactone in different lean BMI/FMI subgroups?

Thanks to your suggestions, we have supplemented the discussion section. We believe that the use of Lean BMI and FMI to evaluate the prognosis of HFpEF patients has positive significance. At the same time, these two indicators provide guidance for guiding patients to conduct exercise rehabilitation and body composition adjustment. At the same time, according to your suggestions, we have improved the analysis of the impact of spironolactone in Lean BMI and FMI for different subgroups, and the results are shown as supplementary material S2 Table. At the same time, we supplemented the use data of spironolactone in the study population in Table 1. I hope these contents can meet your expectations.

2. Several studies have shown that it is the waist circumference (and not BMI) that is a significant risk factor for many cardiovascular disorders and cardiovascular events. I believe at least some of these studies must be discussed in your manuscript since visceral fat, lean body mass, and fat mass are greatly emphasizing the waist circumference over BMI. Here are some articles that I recommend to add to your manuscript: PMID: 32020062 (discusses importance of waist circumference) ,PMID: 37227560 ( shows significant association between major cardiovascular events including heart failure and waist circumference, I highly recommend both)

Thank you for your suggestion. Waist circumference is indeed an important risk factor for many cardiovascular diseases and cardiovascular events. To this end, we show the effect of waist circumference on the primary endpoint and all cuase death of patients in Table 2. As you said, waist circumference is a very important factor. Lean BMI and FMI include waist circumference as an important indicator in the calculation process, which can also partially reflect the important position of waist circumference in our study. Regarding the reference PMID: 32020062 you recommended, we appreciate your help and have included it in our references, which is very helpful for our discussion. Regarding the reference PMID: 37227560, unfortunately, we read this article and found it not relevant to our research, so we did not include it. However, your caption inspired us, and we included more content mentioned in your caption and discussed it, and also added relevant references. Thank you very much for your suggestions, and I hope these contents can meet your expectations.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Amir Hossein Behnoush, Editor

Association of predicted lean body mass and fat mass with prognosis in patients with heart failure preserved ejection fraction

PONE-D-24-54649R1

Dear Dr. pei,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Amir Hossein Behnoush

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: I think the article improved after the authors addressed the minor revisions requested. The discussion has been expanded accordingly

Reviewer #2: thank you for your revision. All comments have been addressed and all questions have been addressed appropriately.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes:  Massimo Mapelli

Reviewer #2: Yes:  Alireza Ramandi

**********

Formally Accepted
Acceptance Letter - Amir Hossein Behnoush, Editor

PONE-D-24-54649R1

PLOS ONE

Dear Dr. pei,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Amir Hossein Behnoush

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .